In this exclusive video, Eric Lawitz, MD, from the Texas Liver Institute, University of Texas Health, San Antonio, spoke about DUR-928, a daily oral treatment for nonalcoholic steatohepatitis.DUR-928 was well tolerated at 50 mg, 150 mg and 300 mg, with no serious adverse events reported, according to Lawitz. At 4 weeks, the median liver fat reduction was –18% at 50 mg, –19% at 150 mg and –23 at 300 mg as measured by MRI-PDFF.Lawitz said that DUR-928 showed overall improvement in multiple markers such as liver enzymes, liver imaging and serum lipid profiles.Read More